200
Participants
Start Date
April 30, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
April 30, 2025
Experimental
Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Minho
OTHER